Historically, caution has been taken when prescribing spironolactone without additional RAAS modulating drugs such as ACE-I or ARBs in patients with heart disease due to concern for upregulation of upstream RAAS metabolites associated with negative cardiovascular effects, such as AngII. This evidence concerns the gene ACE and heart disorder.